ProfileGDS5678 / 1430610_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 41% 42% 42% 41% 46% 45% 41% 42% 42% 41% 40% 42% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0128942
GSM967853U87-EV human glioblastoma xenograft - Control 22.9465841
GSM967854U87-EV human glioblastoma xenograft - Control 32.9721542
GSM967855U87-EV human glioblastoma xenograft - Control 42.9191942
GSM967856U87-EV human glioblastoma xenograft - Control 52.9023141
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1652546
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1296545
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9350241
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.937642
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.957942
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9497541
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8917940
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9635142
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9321241